We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now


It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

RKT Reckitt Benckiser Group Plc

-70.00 (-1.54%)
Last Updated: 09:18:31
Delayed by 15 minutes
Reckitt Benckiser Investors - RKT

Reckitt Benckiser Investors - RKT

Share Name Share Symbol Market Stock Type
Reckitt Benckiser Group Plc RKT London Ordinary Share
  Price Change Price Change % Share Price Last Trade
-70.00 -1.54% 4,468.00 09:18:31
Open Price Low Price High Price Close Price Previous Close
4,500.00 4,426.00 4,501.00 4,538.00
more quote information »
Industry Sector

Top Investor Posts

Top Posts
Posted at 21/3/2024 09:00 by scepticalinvestor
Methinks poor chum strawberry is substantially down on his investment here. CondolencesThankfully us new investors (post fall) will have a lot to gain from these levels
Posted at 16/3/2024 12:30 by dealy
Normally, such a case requires conclusive proof that the product was directly at fault, above and beyond the associated warnings. Proving fault is difficult and expensive because it has to be conclusive. Investors are reacting as if they FDA had found the product to be unsuitable, whereas, in fact, just one judge / jury has deemed them to be at fault. That is not the same as an expert safety committee
Posted at 16/3/2024 06:04 by unastubbs
some broker comment

James Edwardes Jones, at the broker
RBC Europe, said that the ruling had
come “from completely left field. We
didn’t know this was an issue. Reckitt is
culpable in not warning investors specifically
that this was a risk, in our view.”
Analysts at Bernstein calculated that,
based on the number of outstanding
cases, “if the problem was shared
equally between Abbott and Reckitt,
that would be a $30 billion hit for
Abbott and a £23.6 billion hit for Reckitt
[or two thirds of its market cap].”

JP Morgan considered such a worstcase
scenario unlikely, however, saying:
“Reckitt plans to appeal this decision as
the company does not believe that the
plaintiff submitted sufficient evidence
and claims there were numerous errors
made in the trial.”
Posted at 15/3/2024 16:07 by cynicalsteve
Never invest in UK listed companies that do a lot of business in America. The USA is a protectionist, xenophobic country. They took all our money during WW2 (and expect us to thank them for it!) and never miss a chance to repeat the trick, just ask BP investors.
Posted at 15/3/2024 15:04 by justiceforthemany
Who's bothered to contact Investor Relations?
Posted at 29/2/2024 14:36 by unastubbs
RBC Capital Markets lowers target price on Reckitt - Share cast News

Analyst at RBC Capital Markets lowered their target price on consumer goods company Reckitt from 7,500.0p to 7,000.0p on Thursday but reiterated their 'outperform' rating on the stock, stating it was currently "bruised but undervalued".
RBC Capital said there was "a decent business" trying to be heard at Reckitt, but noted that right now it was not getting much airtime. Unlike previous hiatuses, Reckitt's "trade-spend reporting anomaly" cannot be attributed to circumstances outside the company's control and has dented the bank's confidence in the firm.

Reckitt recently identified "an understatement of trade spend in two Middle Eastern markets related to the fourth quarter and prior quarters of 2023. Following an investigation, Reckitt concluded "a small group of employees" had acted inappropriately and as a result, full-year net revenues were £55.0m lower than previously expected.

"That said, it does make sense that this was an isolated incident, if only because it seems to have been so inept on the part of the culprits. They were always going to be found out. We believe Reckitt is meaningfully undervalued and that this will not persist indefinitely, whether it's the stock market or some other investor that resolves it," said RBC. "We appreciate that Reckitt is the progenitor of this latest misfortune, but can't help thinking that if we're right and at the heart of Reckitt there's a business with good brands in good categories being competently managed, this undervaluation cannot persist indefinitely."

The Canadian bank noted that it couldn't say whether the mechanism of resolving this undervaluation would be the shares' re-rating on the back of less accident-prone financial results or the emergence of a trade or financial buyer, but it stated it was "not inclined" to describe Reckitt in 'value trap' terms and, consequently, expects the gap with its target price to narrow, leading to it also reiterating its 'outperform' rating on the stock.

Reporting by Iain Gilbert at
Posted at 29/2/2024 00:12 by philanderer
Investors Chronicle :

Posted at 28/2/2024 13:58 by careful
Hard to believe that anyone makes money investing in UK listed shares.
Even our own pension funds avoid them.
Most private investors lose money.
The cult of equities is over
Posted at 15/12/2023 04:02 by unastubbs
From this week's Moneyweek

A professional investor tells us where he’d put his money. This week: James Harries, STS Global Income & Growth Trust, highlights three favourites

The second company we highlight today is Reckitt Benckiser (LSE: RKT). It is a business that will be familiar to many owing to its well-known brands, such as Dettol and Nurofen. This consumer-health and household-products company has had a lacklustre few years owing to many problems that we now think are being fixed. Following a three-year turnaround, Reckitt is now well on its way to generating stable and reliable growth. Despite the market’s scepticism, reflected in the company’s lowest valuation in a decade, Reckitt has achieved high-single-digit like-for-like sales growth since 2019, alongside enhanced capital efficiency and reduced financial leverage. Reinforcing confidence in its future, Reckitt raised its dividend by 5% last year, ending a prolonged period of stagnation, and announced a significant share-buyback programme, signalling strong growth prospects ahead.
Posted at 16/9/2022 13:42 by philanderer
Reckitt Benckiser is still on a path to glory, says Troy

Troy manager James Harries is ‘disappointed and surprised’ by the departure of Reckitt Benckiser (RKT) boss Laxman Narasimhan but says the consumer goods giant is still on a path back to its former glories.

Harries has held the owner of the Clearasil and Air Wick in his Trojan Global Income fund, where it makes up 4.7% of the £946m portfolio, since 2018, topping up the holding in 2019 when Narasimhan took over.

Harries said Narasimhan brought a ‘renewed focus on execution, investing significant resources to improve procurement, accelerate new product development and increase marketing effectiveness’.

‘Despite the distortions from Covid, the new strategy is starting to bear fruit and Reckitt is returning to its former glory,’ he said.

‘Organic growth is improving, volume growth is encouraging and margins are recovering.’

While he was ‘disappointed and surprised’ by Narasimhan’s departure for Starbucks, Harries said the ‘investment case remains intact’.

‘As long-term investors, chief executive departures are to be expected. Our investment in Reckitt is predicated on the strength of the brands in growing yet defensive categories, not on the charisma of any particular person leading the business,’ he said.

Shares in Reckitt Benckiser closed down 2.9% at £63.72 on Thursday, having largely bounced back after the announcement of Narasimhan’s departure.

Your Recent History

Delayed Upgrade Clock